Joshua Disbrow - Aytu BioScience CEO, Director
AYTU Stock | USD 1.61 0.01 0.62% |
CEO
Mr. Joshua R. Disbrow is Chairman, Chief Executive Officer, Director of the Company. Joshua R. Disbrow was employed by us since April 16, 2015 and a member of our Board of Directors since January 2016. Prior to the closing of the merger with Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. that formed Aytu BioScience, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals LLC, a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that companys second fulltime employee. Mr. Disbrow led the companys commercial efforts from inception to the companys acquisition in 2010 and growth to over 127 million in net sales in 2011. By the time Mr. Disbrow departed Arbor in late 2012, he handled the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 17 years in the pharmaceutical, diagnostic and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations and commercial strategy. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company since 2016.
Age | 49 |
Tenure | 8 years |
Professional Marks | MBA |
Address | Denver Corporate Center III, Denver, CO, United States, 80237 |
Phone | (720) 437-6580 |
Web | https://aytubio.com |
Aytu BioScience Management Efficiency
The company has return on total asset (ROA) of (0.0106) % which means that it has lost $0.0106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4724) %, meaning that it created substantial loss on money invested by shareholders. Aytu BioScience's management efficiency ratios could be used to measure how well Aytu BioScience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.46 in 2024. Return On Capital Employed is likely to drop to -1.07 in 2024. At this time, Aytu BioScience's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 124 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 4.3 M in 2024.Similar Executives
Found 9 records | CEO Age | ||
David RPh | Evoke Pharma | 60 | |
James Hall | Lifecore Biomedical | 61 | |
Amy Trombly | Sonoma Pharmaceuticals | 56 | |
David Gonyer | Evoke Pharma | 60 | |
Sheldon Koenig | Esperion Therapeutics | 58 | |
Isao Teshirogi | Shionogi Co Ltd | 64 | |
Paul Josephs | Lifecore Biomedical | 59 | |
Clifford Starke | Flora Growth Corp | 40 | |
Keith Kendall | Aquestive Therapeutics | 66 |
Management Performance
Return On Equity | -0.47 | ||||
Return On Asset | -0.0106 |
Aytu BioScience Leadership Team
Elected by the shareholders, the Aytu BioScience's board of directors comprises two types of representatives: Aytu BioScience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aytu. The board's role is to monitor Aytu BioScience's management team and ensure that shareholders' interests are well served. Aytu BioScience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aytu BioScience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Joshua Disbrow, CEO, Director | ||
Russ McMahen, Senior Development | ||
Mark CPA, Secretary CFO | ||
Christopher Brooke, Chief Officer | ||
Margaret Cabano, Vice Operations | ||
Topher Brooke, Chief Officer | ||
Greg Pyszczymuka, Chief Officer | ||
Ryan CPA, Executive Optimization | ||
Victoria Cordova, Vice Culture | ||
Jarrett Disbrow, COO, Director |
Aytu Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aytu BioScience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.47 | ||||
Return On Asset | -0.0106 | ||||
Profit Margin | (0.20) % | ||||
Operating Margin | (0.04) % | ||||
Current Valuation | 6.41 M | ||||
Shares Outstanding | 6.15 M | ||||
Shares Owned By Insiders | 2.43 % | ||||
Shares Owned By Institutions | 34.04 % | ||||
Number Of Shares Shorted | 120.8 K | ||||
Price To Earning | (0.77) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.